A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient’s body and responses to treatment.
Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive.
Now, researchers at the Stanford University School of Medicine have devised a way to quickly bring the technique to the clinic. Their approach, which should be broadly applicable to many types of cancers, is highly sensitive and specific. With it they were able to accurately identify about 50 percent of people in the study with stage-1 lung cancer and all patients whose cancers were more advanced.
“We set out to develop a method that overcomes two major hurdles in the circulating tumor DNA field,” said Maximilian Diehn, MD, PhD, the CRK Faculty Scholar and assistant professor of radiation oncology. “First, the technique needs to be very sensitive to detect the very small amounts of tumor DNA present in the blood. Second, to be clinically useful it’s necessary to have a test that works off the shelf for the majority of patients with a given cancer.”
The researchers describe their findings in a paper published online April 6 in Nature Medicine. Diehn shares senior authorship with Ash Alizadeh, MD, PhD, assistant professor of medicine. Postdoctoral scholars Aaron Newman, PhD, and Scott Bratman, MD, PhD share lead authorship.
“We’re trying to develop a general method to detect and measure disease burden,” said Alizadeh, a hematologist and oncologist. “Blood cancers like leukemias can be easier to monitor than solid tumors through ease of access to the blood. By developing a general method for monitoring circulating tumor DNA, we’re in effect trying to transform solid tumors into liquid tumors that can be detected and tracked more easily.”
Even in the absence of treatment, cancer cells are continuously dividing and dying. As they die, they release DNA into the bloodstream, like tiny genetic messages in a bottle. Learning to read these messages — and to pick out the one in 1,000 or 10,000 that come from a cancer cell — can allow clinicians to quickly and noninvasively monitor the volume of tumor, a patient’s response to therapy and even how the tumor mutations evolve over time in the face of treatment or other selective pressures.
“The vast majority of circulating DNA is from normal, non-cancerous cells, even in patients with advanced cancer,” Bratman said. “We needed a comprehensive strategy for isolating the circulating DNA from blood and detecting the rare, cancer-associated mutations. To boost the sensitivity of the technique, we optimized methods for extracting, processing and analyzing the DNA.
The researchers’ technique, which they have dubbed CAPP-Seq, for Cancer Personalized Profiling by deep Sequencing, is sensitive enough to detect just one molecule of tumor DNA in a sea of 10,000 healthy DNA molecules in the blood. Although the researchers focused on patients with non-small-cell lung cancer (which includes most lung cancers, including adenocarcinomas, squamous cell carcinoma and large cell carcinoma), the approach should be widely applicable to many different solid tumors throughout the body. It’s also possible that it could one day be used not just to track the progress of a previously diagnosed patient, but also to screen healthy or at-risk populations for signs of trouble.
Tumor DNA differs from normal DNA by virtue of mutations in the nucleotide sequence. Some of the mutations are thought to be cancer drivers, responsible for initiating the uncontrolled cell growth that is the hallmark of the disease. Others accumulate randomly during repeated cell division. These secondary mutations can sometimes confer resistance to therapy; even a few tumor cells with these types of mutations can expand rapidly in the face of seemingly successful treatment.
Different from patient to patient
“Cancer is a genetic disease,” Alizadeh said. “But unlike Down syndrome, for example, which has a single dominant cause, for most cancers it’s very difficult to identify any one particular genetic aberration or mutation that is found in every patient. Instead, each cancer tends to be genetically different from patient to patient, although sets of mutations can be shared among patients with a given cancer.”
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- Researchers study the risk of false positives in colon cancer screeningon December 2, 2019 at 8:02 am
The objective of this study has been to estimate the cumulative risk of a false positive in the fecal occult blood test during 7 rounds of screening and to identify its associated factors in a ...
- Prostate cancer test: The home urine test that could revolutionise diagnosison December 2, 2019 at 1:31 am
as well as ruling out those who do not have prostate cancer. The test cuts down the need for a barrage of other procedures, including biopsies, blood tests, a physical examination known as a digital ...
- New Movember-Funded Home Urine Test Could Revolutionize Prostate Cancer Diagnosison December 2, 2019 at 1:30 am
The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination (DRE), an MRI scan or a biopsy. "Prostate cancer usually develops ...
- Prostate Cancer Diagnosis: At-Home Urine Test May Soon Be Availableon December 1, 2019 at 11:44 pm
It also allows doctors to determine whether patients will require treatment in the future. "The most commonly used tests for prostate cancer include blood tests, a physical examination known as a ...
- Prostate cancer screening: Scientists develop an at-home urine teston December 1, 2019 at 9:15 pm
the researchers recruited 14 men whom they subjected to a range of medical tests including a digital rectal examination, which is one of the main methods of detecting prostate cancer (along with blood ...
- This Simple Finger Test Could Reveal Signs of Lung Cancer and Other Health Conditionson November 29, 2019 at 12:00 am
A simple finger test which you can do yourself could reveal the presence of an underlying health condition, including lung cancer. The so-called Schamroth window test helps to ... This is caused by ...
- Home urine test for prostate cancer could revolutionize diagnosison November 28, 2019 at 11:56 pm
However, doctors struggle to predict which tumors will become aggressive, making it hard to decide on treatment for many men. "The most commonly used tests for prostate cancer include blood tests, a ...
- Lung Cancer: This Simple Finger Test Could Help Identify Conditionon November 28, 2019 at 10:18 pm
But further deaths may be prevented with a simple test at home. The test, called the Schamroth window test ... "Clubbing is thought to be caused by fluid collecting in the soft tissues at the end of ...
- This Revolutionary Technology Accurately Detects 13 Types Of Cancer Using Single Drop Of Bloodon November 28, 2019 at 3:22 am
Other companies like Toray Industries Inc. have already designed similar devices that can detect cancer using miRNA molecules from a patient’s blood sample. "Compared to other companies' methods ...
- Many Mutations Detected in Liquid Biopsy Tests Do Not Come from Cancer Cells, an MSK Study Findson November 25, 2019 at 10:13 am
Blood tests called liquid biopsies have raised hopes among doctors and patients that diagnosing and screening for cancer could be as simple as a blood draw. These sensitive genetic tests can identify ...
via Bing News